Liver Transplantation

The answer first

Liver Transplantation is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Liver Transplantation to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Ma Z, Niu Z, Yu A, Guo Y, et al. Severe hepatotoxicity associated with orlistat: clinical presentation, risk factors and outcomes Front Pharmacol, 2026.PMID 42465996
2. [2]Tapia-Villacis S, Prieto J, López M, Medina J Disseminated Phaeohyphomycosis Due to Alternaria alternata in a Liver Transplant Recipient: Successful Treatment With Isavuconazole, a Case Report and Literature Review Case Rep Transplant, 2026.PMID 42465679
3. [3]Lee H, Jung KU, Luu M, Kosari K, et al. Perioperative mortality and survival after lymph node excision in hepatocellular carcinoma: a national cancer database propensity score-matched cohort study World J Surg Oncol, 2026.PMID 42464368
4. [4]Morales Junior R, Telles JP, Chua NGS, Kunicki PK, et al. Mapping Therapeutic Drug Monitoring Research in Low- and Middle-Income Countries: A Scoping Review (2015-2024) Ther Drug Monit, 2026.PMID 42457203
5. [5]You H, Maiwall R, Chen J, Ahn SH, et al. APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update Hepatol Int, 2026.PMID 42365189
6. [6]Perito ER, Chen JK, Danziger-Isakov LA, Desai MS, et al. AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Post-transplant management Liver Transpl, 2026.PMID 42329162
7. [7]Doan HN, Chang MC Comparative Effectiveness of Unstable Versus Stable Resistance Training on Lower Limb Strength, Mobility, and Fear of Falling in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials Am J Phys Med Rehabil, 2026.PMID 42468010
8. [8]Liu HW, Tsai TL Virtual Reality-assisted Physiotherapeutic Training for Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis Am J Phys Med Rehabil, 2026.PMID 42468005
9. [9]Osborne AK, Brown RD, Sillence E Effects of Social Media Narratives on Affective and Behavioral Responses to Menopause Content: Randomized Online Experimental Study JMIR Form Res, 2026.PMID 42467962
10. [10]Liu WY, Lian LY, Kim SU, Yip TC, et al. Characteristics and outcomes of patients with imaging-defined MASLD and histological steatosis grade S0 Am J Gastroenterol, 2026.PMID 42467969
11. [11]Premkumar M, Sandhu A, Sharma P, Nain J, et al. Recompensation of decompensated cirrhosis in a spectrum of metabolic-dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors Hepatology, 2026.PMID 42467948
12. [12]Bozzi E Dr, Bianchi F Dr, Lorenzoni G Dr, Giuliano A Dr, et al. Radiation Segmentectomy for Hepatocellular Carcinoma: Redefining the Limits of Curative-Intent Therapy Br J Radiol, 2026.PMID 42467837